Catalent Inc - Company Profile
Powered by 
All the data and insights you need on Catalent Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Catalent Inc Strategy Report
- Understand Catalent Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
Catalent Inc (Catalent) provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex advanced formulation delivery technologies, and related integrated solutions. It provides comprehensive pre-formulation, development, and both clinical and commercial scales for most traditional and advanced oral solid dose formats. Catalent also offers a wide range of injectable manufacturing solutions including filling drugs or biologics into pre-filled syringes and glass-free vials as well as formulation development and cell-line manufacturing. The company has manufacturing facilities in North America and Europe. Catalent is headquartered in Somerset, New Jersey, the US.
Headquarters
United States of America
Address
14 Schoolhouse Rd, Somerset, New Jersey, 08873-1213
Website
www.catalent.com
Telephone
1 732 5376200
No of Employees
17,800
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CTLT (NYSE)
Revenue (2022)
$4.3B
-11.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-151.3%
(2022 vs 2021)
Market Cap*
$10.2B
Net Profit Margin (2022)
XYZ
-157.8%
(2022 vs 2021)
* As of and is in US$
Catalent Inc premium industry data and analytics
Products and Services
| Services |
|---|
| - |
| Softgel Technologies: |
| Formulation, Development and Manufacturing Services for Soft Capsules or Softgels |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company collaborated with Invenra to develop novel bispecific antibody-drug conjugates. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement to be acquired by Novo Holdings. |
| 2023 | Others | In June, the company expanded its integrated development, manufacturing and supply solution, OneBio Suite. |
Competitor Comparison
| Key Parameters | Catalent Inc | IQVIA Holdings Inc | ICON Plc | Charles River Laboratories International Inc | Revvity Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Somerset | Durham | Dublin | Wilmington | Waltham |
| State/Province | New Jersey | North Carolina | Dublin | Massachusetts | Massachusetts |
| No. of Employees | 17,800 | 87,000 | 41,100 | 20,000 | 11,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| J. Martin Carroll | Chairman | Executive Board | 2023 | 73 |
| Alessandro Maselli | Director; President; Chief Executive Officer | Executive Board | 2022 | 51 |
| Matti Masanovich | Chief Financial Officer; Senior Vice President | Senior Management | 2023 | - |
| Karen Santiago | Chief Accounting Officer; Vice President | Senior Management | 2022 | - |
| Charles Lickfold | Senior Vice President; Chief Information Officer | Senior Management | 2020 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward